Sinopharm's presentation on their Beijing vaccine to WHO's expert committee is now online: cdn.who.int/media/docs/def… 1/n HT @AlejandrodeBar1
...Includes this overview of preclinical toxicity studies. (Note, they've also published this study on some preclinical work tandfonline.com/doi/full/10.10…) ...2/n
...The phase 3, #4Humanity trial in the Middle East - here are the blood collections taken across all the countries. (No answer here to the question of whether there were regular tests for Covid-19 in the UAE part of the trial)...3/n
...Breakdown of participants by country: about 11,000 people from outside the UAE...4/n
...Breakdown of participants just in the Beijing vaccine & placebo arms. <14% non-Asian. (Would have been helpful to see this defined, but we haven't seen a protocol for this trial yet)...5/n
...2 doses were 3 weeks apart, vaccine efficacy calculated from 14 days after the 2nd dose:

- Against Covid-19, 78.1% (CI 76-86) - *appears not to be only symptomatic Covid-19*

- 0 severe Covid-19 in vax group, 2 in placebo

...6/n
...I wish this was explained here or in WHO summary. Rate against asymptomatic infection only - doesn't say how that was detected:
- 50.4% (CI: -2 to 76) (11 in vax group, 22 in placebo)

Listed under subgroup analyses, implying the overall efficacy isn't only symptomatic ...7/n
...Solicited adverse events for the whole group. Placebo is blue: higher than vax for mild (grade 1) events. No difference for other levels of events. This is such a low rate rate of adverse reactions to Covid vaccine injections...8/n
...Incidence of adverse events displayed in 3 time periods (blue is placebo) ...9/n
... Serious adverse events (SAEs). In 2 people, they were vax-related, but events not described. (My explainer on the language of AEs: absolutelymaybe.plos.org/2021/02/21/a-r…) ...10/n
...Very few people aged 60+ in this trial. Here are neutralizing antibodies in a small subset of the under-60s vs most of the vaxed aged 60+ (172 out of 294).

So a larger proportion of older people would seem likely to have reduced overall vaccine efficacy ...11/n
...There's a post-marketing study for 9,800 people in Mozambique for Beijing vax, with co-administration (but it doesn't say what - flu vaccine?). If anyone knows more details of this study, please let me know!

They thanked the research participants at the end. #4Humanity 12/12

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Hilda Bastian, PhD

Hilda Bastian, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @hildabast

6 May
They've registered Sputnik Light in Russia, again on very thin data, again not waiting for phase 3. It's not a new vaccine: it's the 1st half of Sputnik V - an adenovirus 26 shot. Given the production problems since early on with the other half (Ad5)...1/n sputnikvaccine.com/newsroom/press…
...it's not surprising. (The Ad5 shot is the one there was a lot of controversy about recently because of replication-competence.) So it becomes a single-shot adenovirus vax (like J&J's & CanSino's) & it's half the price: full Sputnik V was expensive for Covid vax...2/n
...The data basis? 3 things: Immunogenicity results of a phase 1/2 trial with 110 people - some outcomes summarized in the press release only. Here's the trial register entry for it...3/n clinicaltrials.gov/ct2/show/NCT04…
Read 10 tweets
5 May
Results of an analysis of adverse events after Sputnik V vax in San Marino. From those vaccinated early, so some healthcare workers & mostly older people. Median age 68, so a much lower rate would be expected than for a general population ...1/n (Preprint) medrxiv.org/content/10.110… Image
...Everyone who got vaccinated was invited to participate, but it appears to have had a very low response rate: eg 1,946 out of 8,799 aged 60-89 did (22%): nothing reported to gauge how similar they were to those who didn't. Total group is 2,588, of whom 1,288 had both shots..2/n
...People were contacted 7 days after vaccination, then at 1 month & 3 months. So there would be more recall bias than in a trial with a diary method, but less recall bias at 7 days than for later data...3/n
Read 5 tweets
5 May
Oh my! Detail on adverse events in the Novavax UK trial included in a conference presentation - wish the numbers were there: definitely less than Moderna. Will need to blow this up & try to work it out! ...1/n novavax.com/sites/default/… HT @londonboyjohn Image
...A reminder of the vaccine efficacy rates for the phase 3 trial in the UK & the 2b efficacy trial in South Africa. It's an adjuvanted protein subunit vaccine...2/n Image
...They've made a booster aiming at the B.1.351 variant of concern. Here you see responses in baboons that had been immunized with the original a year ago. Bonus: you see with & without their adjuvant (same one used in the recently reported malaria vaccine) ...3/n Image
Read 5 tweets
3 May
The evidence assessments - but not the WHO decisions - for Sinopharm's Beijing vax & Sinovac's CoronaVac are going up on the WHO website who.int/news-room/even… HT @lutl88 @hvasquezhg ...1/n
...Sinopharm Beijing: WHO assessment. 45,000-participant trial in UAE/Bahrain/Egypt/Jordan, doses 21 days apart, efficacy:

- Overall: 78.1% (CI 65-86)
- For people with no previous infection: 80.8% (67-89) (the usual efficacy rate for others)

cdn.who.int/media/docs/def… ...2/n
...- Efficacy against hospitalization: 78.7% (CI 26-94)
- 1 death only, in the placebo group

But this is only up to age 60: negligible people over 60, & none had Covid-19 (in vax or placebo group)
...3/n
Read 25 tweets
29 Apr
Anvisa (Brazil's drug regulator) just held a press conference on Sputnik V, including responding to the developers' allegations about their assessment & decision. You can see it here Live-tweeted (in Portuguese) by @jasonptodd ..1/n
...They confirmed the presence of replication-competent adenovirus in Ad5 (2nd shot) batches wasn't a finding of their own batch testing - it was reported to them by Gameleya (developers of Sputnik V), who had apparently set a high level of acceptable replication-competence...2/n
...for the Ad5 shot (but not for the 1st, Ad26, dose). They pointed to the US FDA standard for this, here: fda.gov/media/113760/d… That's what they expected Gamaleya to certify. However, apparently Gamaleya set the level at 300, not 3 ...3/n
Read 10 tweets
26 Apr
Anvisa (Brazil's drug regulator) has just announced it has denied the request to import Sputnik V vaccine because of absence of data & issues with the development of the vaccine, including vax quality. g1.globo.com/bemestar/vacin… Meeting still streaming ..1/n
...Unanswered questions about the vaccine include basic biological data about its actions in the body, data on adverse events (including questions about thromboembolic events) ...2/n
...I think with all the focus on Lancet paper for phase 3, people forget how little study there had been of this vax: eg only 38 people in phase 1/2 trial version with lots of problems. (absolutelymaybe.plos.org/2020/09/11/pha…) Assessing a vaccine isn't only about the phase 3 trial results...3/n
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(